Stealth, AOBiome propose Hong Kong offerings
Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on July 3 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX).
Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that binds and stabilizes cardiolipin to promote electron transfer and prevent apoptosis. The candidate is in a global Phase III trial to treat mitochondrial myopathy and a Phase II/III trial to treat Barth syndrome. Stealth plans to start a Phase IIb trial of the candidate to treat dry age-related macular degeneration (AMD) around year end and a Chinese Phase II/III trial to treat Leber’s hereditary optic neuropathy (LHON) in 1H19...
BCIQ Company Profiles